Navigation Links
Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
Date:3/17/2010

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.  Hydrocodone is the most widely prescribed drug in the United States, but there are currently no products available with hydrocodone only, or with controlled-release formulations.  ZX002, which incorporates Elan's proprietary SODAS® technology, offers a unique controlled-release profile which utilizes both immediate release and extended release properties designed to enable twice daily dosing.

"We are pleased to be initiating this pivotal Phase 3 trial of ZX002 as the first single-entity, controlled-release hydrocodone formulation," said Cynthia Robinson, Ph.D., chief development officer of Zogenix.  "We believe this hydrocodone therapy could offer significant benefits to both the patient and the practicing physician by allowing for less frequent dosing with a customized controlled-release profile and the ability to titrate to higher hydrocodone doses than currently recommended for hydrocodone products burdened by combination formulations. Further, we believe ZX002 may offer patients an option for the treatment of their chronic pain that potentially avoids some of the serious side effects that can accompany chronic use of combination opioids that contain acetaminophen, or other n
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
2. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
3. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
4. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
5. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
6. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
7. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
8. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... With obesity in America reaching alarming levels -- across our adult and youth ... who used BodyMedia,s wearable body-monitoring technology either in conjunction with a group weight loss ... three times more weight than individuals who attempted ... ...
... Ill., March 11 The U.S. Food ... supplemental new drug application (sNDA) of a new six-month ... Depot (leuprolide acetate for depot suspension) for ...  Palliative treatment helps to relieve symptoms associated with advanced ...
Cached Medicine Technology:The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7
(Date:7/12/2014)... 2014 The fastest-growing mobile technology is ... measurement of LTE networks continues to grow due to ... devices have increased mobile data traffic, which is a ... market. Communications Test and Measurement equipment comply with industry ... Communications Test and Measurement Market is estimated to grown ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 "The second toes ... uncomfortable and painful to wear shoes," said an inventor from ... sock that prevents this from happening. , He then created ... way to prevent the second and big toes from overlapping. ... while wearing shoes. Ergonomic and easy to use, it's ideal ...
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm ... Lawsuits (case #59776/2014), announces they have launched a new ... the popular hair dye, Just For Men, has caused some ... and other areas. In addition to detailing symptoms that are ... the advertisements being run by Wright & Schulte LLC will ...
Breaking Medicine News(10 mins):Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4
... halted early because of supplement,s poor performance , SATURDAY, ... supplement selenium doesn,t reduce the likelihood of lung cancer ... Daniel D. Karp, a professor in the department of ... Texas M.D. Anderson Cancer Center, is scheduled to present ...
... ... Dad,” and Faces iMake, among Father’s Day 2010 GreatDad Recommends Award and Mr. Dad Seal ... San ... Day activities this year are in for a real treat. Presented by Mr. Dad and ...
... ... and prisons , ... (PRWEB) June 5, 2010 -- President Narconon International, Clark Carr, just finished his fourth ... relapse prevention technology to Mexico. Accompanied by U.S. and Mexican volunteers, Carr demonstrated pain ...
... ... Savory, the Savory Institute and the Africa Centre for Holistic Management are winning awards for ... and rivers back to life, increase food production and security and store carbon in ever ... ...
... According to new research that will be presented on Saturday, ... Academy of Dental Sleep Medicine, the majority of U.S. dental ... sleep disorders, which affect more than 70 million adults in ... - Los Angeles (UCLA) School of Dentistry surveyed each of ...
... According to new research that will be presented on ... the American Academy of Dental Sleep Medicine, between 31 ... sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue ... Mandibular advancement appliances (MAA) have been shown to ...
Cached Medicine News:Health News:Don't Count on Selenium to Prevent Lung Cancer Recurrence 2Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 2Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 3Health News:Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks 4Health News:Narconon Campaigns to Help Mexico Reduce Drug-related Violence in Sonora and Michoacan 2Health News:Holistic Management and Allan Savory Win the 2010 Buckminster Fuller Award for Turning Deserts into Thriving Grasslands and Combating Climate Change. 2Health News:US dental schools leave graduates unprepared to screen for sleep disorders 2Health News:Sleep apnea patients using oral appliance therapy show high efficacy and compliance 2
... slot into the side ... monitor, so patient information ... patient's side. Data is ... and storage at the ...
... Telemetry System is a telemetry system ... which require monitoring and performance. With ... able to monitor patients from virtually ... and wireless bedsides. Now, monitoring your ...
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan Universal ... surgical table for lower and ... head and neck, and lower ... traction package gives you the ...
Medicine Products: